Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU

European Journal of Cancer

Volumn 35, Issue 13, 1999, Pages 1796-1804

  Iveson, T J ^a   Hickish, T ^b   Schmitt, C ^c   Van Cutsem, E ^d  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^c ARCOS   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

5 fluorouracil; Chemotherapy; Cost effectiveness analysis; Irinotecan; Metastatic colorectal cancer; Survival benefit

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032715520     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00186-0     Document Type: Article

References (22)

1. Rougier P, Van Cutsem E, Bajetta E, et al. Phase III trial of irinotecan versus infusional fluorouracil in patients with metastatic colorectal cancer after fluorouracil failure. Lancet 1998, 352, 1407-1412.
2. Schmoll H-J. Colorectal carcinoma: current problems and future perspectives. Ann Oncol 1994, 5(Suppl. 3), SI 15.
3. Van Triest B, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. EurJ Cancer 1995, 31A, 1193-1197.
4. Cancer Research Campaign. Factsheet 18.1 1993.
5. Scheithauer W, Rosen M, Kernek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancr. BrMedJ 1993, 306, 752-755.
6. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997, 15, 368-381.
7. Shimada Y, Rothenberg M, Hilsenbeck SG, et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumour colony-forming units. Anti-Cancer Drugs 1994,5,202-206.
8. Van Cutsem E, Rougier Ph, Droz JP, et al. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997, 16, 268a (abstract).
9. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracilbased chemotherapy. J Clin Oncol 1997, 15, 251-260.
10. Van Cutsem E, Cunningham D, ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). EurJ Cancer 1999, 35, 54-59.
11. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352, 1413-1418.
12. De Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 1997, 15, 808-815.
13. Lokich JJ, Ahigren JD, Gullo JJ, et al. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. J Clin Oncol 1989, 7,425-432.
14. Weh MJ, Wake HJ, Dieriamm J, et al. Weekly therapy with folinic acid (FA) and high-dose fluorouracil (5-FU) 24 hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994, 5, 233-237.
15. British National Formulary. Number 35, March 1998.
16. Schmitt C, Blijham G, Jolain B. Prospective econcomic evaluation of a phase III trial comparing irinotecan with infusional 5-FU in patients with advanced colorectal cancer (abstract). Presented at the 20th meeting of the Society for Medical Decision Making, Cambridge, Massachusetts, U.S.A., 25-28 October, 1998.
17. Department of Health, Government Statistical Service. Hospital episode statistics. Volume 1. Finished consultant episodes by diagnosis, operation and specialty, England: 1992-93.
18. Netten A, Dennett J. Unit Costs of Health and Social Care. PSSRU, University of Kent, 1996.
19. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. EurJ Cancer 1996, 32A(Suppl. 5), S13.
20. Freeberg KA, Paltiel DA. Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. Pharmacoeconomics 1996, 14, 165-174.
21. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization Tentative guidelines for using clinical and economic evaluations? Can MedAssoc J 1992, 146, 473-481.
22. Department of Health, Economic and Operational Research Division, Department of Health, 1994.